Showing results (51-60 of 65) with videos related to
Sort By:
Pageof 7
British Journal of Pharmacology|November 23, 2000
Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkeyS A Douglas, A C Sulpizio, V Piercy, et al.Journal of Cardiovascular Pharmacology|May 22, 1998
Plasma- and cerebrospinal fluid-immunoreactive endothelin-1: effects of nonpeptide endothelin receptor antagonists with diverse affinity profiles for endothelin-A and endothelin-B receptorsR N Willette, C F Sauermelch, B L Storer, et al.Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|February 1, 1997
Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitorsR N Willette, A O Shiloh, C F Sauermelch, et al.The Journal of Pharmacology and Experimental Therapeutics|November 1, 1996
Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone ratsF C Barone, A H Nelson, E H Ohlstein, et al.The Journal of Pharmacology and Experimental Therapeutics|February 22, 2001
Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonistN Aiyar, R A Daines, J Disa, et al.Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|April 19, 2007
P38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1S S Nerurkar, A R Olzinski, K S Frazier, et al.Journal of Cardiovascular Pharmacology|October 6, 2001
Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunctionR N Willette, K M Anderson, A H Nelson, et al.The American Journal of Physiology|July 1, 1990
Distinction of NPY receptors in vitro and in vivo. I. NPY-(18-36) discriminates NPY receptor subtypes in vitroM C Michel, E Schlicker, K Fink, et al.Journal of Cardiovascular Pharmacology|November 15, 2000
Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primateS A Douglas, D J Ashton, C F Sauermelch, et al.The Journal of Pharmacology and Experimental Therapeutics|March 23, 1999
In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure ratsR N Willette, N Aiyar, T L Yue, et al.Pageof 7